The only living, true human skin – on demand

The current standard of care in acute and elective skin surgery is autografting, where healthy skin is harvested from the patient and grafted onto wounds. While the skin surgery market is dynamic and growing – with numerous products supporting autografting, including wound bed preparation products, combination therapies, wound dressings, and scar care products – autografting faces donor site shortage and often results in significant scarring and high macro and micro long-term costs.

After more than 20 years of research and development, CUTISS is redefining skin surgery by replacing autografting with denovoSkin™, a first-in-class, personalized skin tissue therapy.

denovoSkin™ is an advanced therapy medicinal product, bioengineered in scalable quantities from a small, stamp-sized biopsy of a patient’s healthy skin. It is composed of an epidermis (top, protective layer = life) and a dermis (the structural below layer = quality of life) for the permanent treatment of wounds that require skin surgery.

Designed to regenerate in a scarless manner, denovoSkin™ matures quickly, safely restores skin function, significantly reduces the need for scar care and follow-up corrective surgeries, and grows with the patient.

Beyond being life-saving and life-changing, denovoSkin™ is also cost-effective and offers attractive unit economics.

denovoSkin™ is in late-stage clinical trials in Switzerland and the European Union and also accessible under compassionate use. It has been granted Orphan Drug Designation (ODD) for the treatment of burns from Swissmedic, EMA, and the FDA. The ODD status provides fast-track regulatory pathways and extended market exclusivity.